Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 2/3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Mesothelioma 1

Interventions

Pemetrexed 4Cisplatin 4pembrolizumab 3Drug Therapy 2Carboplatin 2toripalimab 1tislelizumab 1spartalizumab 1sintilimab 1penpulimab 1nintedanib 1camrelizumab 1balstilimab 1atezolizumab 1anlotinib 1Vincristine 1Topotecan 1Sentinel Lymph Node Biopsy 1Platinum Compounds 1Melphalan 1Inosine 1Injections 1Indocyanine Green 1Immunotherapy 1Hyperthermia, Induced 1Etoposide 1Cryotherapy 1Bevacizumab 1ADI PEG20 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × nintedanib × Other solid neoplasm × Clear all
NCT01907100 2019-03-18

Nintedanib (BIBF 1120) in Mesothelioma

Boehringer Ingelheim

Phase 2/3 Terminated
545 enrolled 15 charts
Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡